What is the most financially viable vaccine strategy for Chagas disease vaccines? Today UK based vaccine strategic consultancy releases a brand new market analysis MarketVIEW: Chagas disease vaccines.
VacZine Analytics releases MarketVIEW: Chagas disease vaccines
Chagas disease, is caused by the protozoan parasite Trypanasoma cruzi (T.cruzi). T.cruzi mainly infects young children living in poverty and it is estimated that around 10 million people carry the pathogen with 99% living in Latin America. After acute infection most individuals remain in an asymptomatic indeterminate disease phase, which can last for decades. However, around 30 to 40% progress to chronic disease (determinate phase) , which includes serious cardiac and gastrointestinal manifestations. It is estimated that around 10,000 deaths occur each year due to chronic Chagas disease with substantial economic losses.
This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for T.cruzi vaccine profiles in the LATAM, US and EU regions. Two therapeutic vaccine profiles (TX) are modelled in determinate and indeterminate populations to 2034 , along with investigation also of a prophylactic (PX) vaccine profile. The analysis provides an up-to-date review of the literature in terms of epidemiology, treatment, cost implications coupled with a review of vaccine development history to date. Clear assumptions are provided in terms of prospective vaccine launch date, penetration estimates, pricing estimates and gross revenue forecasts.
Access it here
VacZine Analytics is an established strategic research publisher based in the United Kingdom.